Value Dossier Icon

Pharmaceutical companies with R&D in Germany – Benefit for price negotiations

Figure 1: Different price guidelines apply for the AMNOG price negotiations if ≥ 5 % of the study population are German Products with initial market entry after January 1st, 2025 are now benefiting from less strict pricing guidelines if the studies used for AMNOG benefit assessment included ≥ 5 % German patients.

2025-02-05T08:44:10+01:005. February 2025|Allgemein, AMNOG Benefit Assessment, Reimbursement|Comments Off on Pharmaceutical companies with R&D in Germany – Benefit for price negotiations

Confidential reimbursement amount – Only for pharmaceutical companies with R&D in Germany

Figure 1: Requirements, pros and cons for the confidential reimbursement amount in Germany Confidential reimbursement amounts are finally available in Germany. However, the medicinal product and the pharmaceutical company must meet several requirements. Above all, the confidential reimbursement amount will only be available for new medicinal products with initial market entry in

2025-02-05T08:52:08+01:0014. January 2025|Reimbursement|0 Comments
Go to Top